EarningsIncremental ASCO data supports our launch trajectory, indicating a favorable risk/reward setup for Day One as Ojemda enters its first half of commercial sales post-FDA approval.
Financial PerformanceDay One Biopharmaceuticals reported a robust cash position of $473 million, a best-in-class commercial product, an experienced management team, and is currently at its lowest valuation in over 30 months, presenting a buying opportunity with a holding period of at least 12 months.
Market PositionReaffirming commercial trajectory: real-world momentum mirrors clinical confidence, with over 1,600 prescriptions written and $57.2M in net sales achieved, validating market readiness and unmet need.